RADNOR, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024. CONTA ...

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, inclusive (the “Class Period”), have until October 21, 2024 to seek appointment as lead plaintiff of the DexCom class action lawsuit. Captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.), the DexCom class action lawsuit charges DexCom as well as certain of DexCom’s top executives with violations of the Se ...

Legal Investigation - Kuehn Law PLLC is investigating potential breaches of fiduciary duties by DexCom Inc officers and directors [1] - A federal securities lawsuit alleges DexCom insiders misrepresented or failed to disclose material information regarding 2024 revenue expectations [1] Financial Impact - DexCom reduced its full fiscal year 2024 revenue guidance on July 25 2024 [1] - The company attributed the lowered guidance to the execution of several key strategic initiatives that did not meet their high standards [1] - DexCom's stock price fell to $64 00 representing a 40 66% decline following the announcement [1] Shareholder Involvement - Long-term DexCom stockholders are encouraged to contact Kuehn Law for a free consultation regarding the case [2] - Shareholder participation is emphasized as important for maintaining the integrity and fairness of financial markets [3]

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=106365&from=3  CLASS PERIOD: January 8, 2024 to J ...

DexCom, Inc. (DXCM) is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust second-quarter 2024 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition persist.This Zacks Rank #3 (Hold) company’s shares have lost 46.8% year to date against the industry’s 9.9% growth. The S&P 500 Index has increased 21.1% in the same time frame.DXCM, a renowned medical device company and provide ...

DexCom Stock Performance and Market Position - DexCom stock is down by about 53% from its peak in April, despite starting the year with healthy gains [1] - The company markets one of the world's most popular continuous glucose monitors (CGM), which transmit data to smartphones or Apple Watches [1] - DexCom's stock fell by about 40% in July after management lowered its sales guidance, with Q3 sales growth expected to be only 1% to 3% year over year [2] - Full-year revenue expectations were revised down to $4 billion to $4.05 billion, from a previous range of $4.2 billion to $4.35 billion [2] Competitive Landscape - Abbott Laboratories, DexCom's lead competitor, did not issue a similar sales slowdown warning, raising investor concerns [2] - Abbott's FreeStyle Libre CGM sales grew 18.4% year over year in Q2 to $1.6 billion, about 60% more than DexCom's CGM revenue in the same period [3] - Medtronic, another major player, received FDA approval for its first disposable all-in-one CGM in August, intensifying competition [6] - Abbott and Medtronic announced a collaboration combining Abbott's CGM technology with Medtronic's insulin delivery system, potentially strengthening Abbott's market position [7] Market Opportunity and Product Innovation - DexCom's addressable market is large, with 29.4 million diagnosed diabetic adults in the U.S. and an estimated 8.7 million undiagnosed cases [4] - Approximately 38% of U.S. adults have prediabetes, creating additional demand for glucose monitoring [4] - DexCom launched Stelo, an over-the-counter CGM for non-insulin users, in August to tap into the growing market of health-conscious individuals [4] Challenges and Risks - DexCom's forward price-to-earnings ratio of 39.8 is high, suggesting the stock could fall further if the Q3 sales slowdown persists [5] - Eli Lilly's tirzepatide study showed a 94% reduction in the risk of progression to type 2 diabetes, potentially shrinking DexCom's addressable market [6] - DexCom's stock is not considered a bargain at its current valuation, and investors may need to wait for a return to previous growth rates [8]

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in DexCom and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a ...

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM), alleging that the medical device company made misleading statements about its financial performance and growth prospects. Hagens Berman urges DexCom investors who suffered substantial losses to submit your losses now. Class Period: Jan. 8, 2024 – July 25, 2024Lead Plaintiff Deadline: Oct. 21, 2024Visit: www.hbsslaw.com/investor-fraud/DXCM Contact the Firm Now: DXCM@hbsslaw.com       ...